用于HIV-1疫苗的靶向佐剂的研发。
Development of targeted adjuvants for HIV-1 vaccines.
作者信息
Liu Jun, Ostrowski Mario
机构信息
Clinical Sciences Division, University of Toronto, Room 6352, Medical Sciences Building, 1 King's College Circle, Toronto, ON, M5S1A8, Canada.
Department of Immunology, University of Toronto, Toronto, ON, Canada.
出版信息
AIDS Res Ther. 2017 Sep 12;14(1):43. doi: 10.1186/s12981-017-0165-8.
Abstract
Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared with traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent memory response from B cells, CD8 T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4 T cells, especially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in the studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules, TLRs agonists, and NODs agonists.
摘要
寻找新型佐剂是开发有效HIV-1疫苗工作的一个重要组成部分。与传统佐剂相比，在HIV-1预防背景下的现代佐剂能够引发B细胞、CD8 T细胞和NK细胞产生持久且强效的记忆反应，但能避免过度刺激HIV-1易感的CD4 T细胞，尤其是在HIV-1传播的主要途径——生殖器和直肠黏膜处。我们简要回顾了此类潜在靶向佐剂研究的最新进展，重点关注我们所研究的三类分子：肿瘤坏死因子超家族（TNFSF）分子、Toll样受体（TLRs）激动剂和核苷酸结合寡聚化结构域（NODs）激动剂。
相似文献
1
Development of targeted adjuvants for HIV-1 vaccines.用于HIV-1疫苗的靶向佐剂的研发。
AIDS Res Ther. 2017 Sep 12;14(1):43. doi: 10.1186/s12981-017-0165-8.
2
Development of TNFSF as molecular adjuvants for ALVAC HIV-1 vaccines.作为禽痘病毒载体的HIV-1疫苗分子佐剂的肿瘤坏死因子超家族（TNFSF）的研发。
Hum Vaccin. 2010 Apr;6(4):355-9. doi: 10.4161/hv.6.4.10867. Epub 2010 Apr 6.
3
Immunostimulatory combinations: designing the next generation of vaccine adjuvants.免疫刺激组合：设计下一代疫苗佐剂
J Leukoc Biol. 2006 Nov;80(5):1084-102. doi: 10.1189/jlb.0306147. Epub 2006 Aug 24.
4
Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.艾滋病疫苗转化研究迷你综述系列：利用固有免疫研发艾滋病疫苗
Clin Exp Immunol. 2009 Aug;157(2):174-80. doi: 10.1111/j.1365-2249.2009.03928.x.
5
Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.自然杀伤T细胞和TLR9激动剂作为C组HIV-1包膜蛋白舌下疫苗接种的黏膜佐剂。
Vaccine. 2014 Dec 5;32(51):6934-6940. doi: 10.1016/j.vaccine.2014.10.051. Epub 2014 Nov 2.
6
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.多聚体可溶性CD40配体和糖皮质激素诱导肿瘤坏死因子受体配体作为人类免疫缺陷病毒DNA疫苗的佐剂
J Virol. 2006 Feb;80(4):1762-72. doi: 10.1128/JVI.80.4.1762-1772.2006.
7
HIV/AIDS vaccines: 2007.艾滋病毒/艾滋病疫苗：2007年。
Clin Pharmacol Ther. 2007 Dec;82(6):686-93. doi: 10.1038/sj.clpt.6100408. Epub 2007 Oct 31.
8
The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.OX40配体（CD252）对HIV-1金丝雀痘疫苗的佐剂作用。
Vaccine. 2009 Aug 13;27(37):5077-84. doi: 10.1016/j.vaccine.2009.06.046. Epub 2009 Jun 30.
9
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.基于新型阳离子佐剂 CAF01 的 18 个 T 细胞最小表位肽的新型治疗性 HIV-1 疫苗的研发和临床前安全性评价。
Vaccine. 2011 Sep 16;29(40):7067-74. doi: 10.1016/j.vaccine.2011.07.025. Epub 2011 Jul 19.
10
Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.新型 HIV 白细胞介素-4 受体拮抗剂疫苗策略可诱导高亲和力的 CD8 T 细胞和 B 细胞免疫，具有更高的保护效力。
Vaccine. 2014 Sep 29;32(43):5703-14. doi: 10.1016/j.vaccine.2014.08.023. Epub 2014 Aug 20.
引用本文的文献
1
Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity.采用反向疫苗学方法设计针对人呼吸道合胞病毒的肽基疫苗：免疫原性、抗原性、致敏性和毒性评估
Front Immunol. 2025 Mar 28;16:1546254. doi: 10.3389/fimmu.2025.1546254. eCollection 2025.
2
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.探索临床前和临床环境中的 HIV 疫苗进展：从历史到未来展望。
Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368.
3
An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses.基于 MVA 的载体表达无细胞 ISG15 可增加 IFN-I 的产生并改善 HIV-1 特异性 CD8 T 细胞免疫应答。
Front Cell Infect Microbiol. 2023 May 29;13:1187193. doi: 10.3389/fcimb.2023.1187193. eCollection 2023.
4
Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso.利用 PPLasso 对高维数据进行预后和预测生物标志物的鉴定。
BMC Bioinformatics. 2023 Jan 23;24(1):25. doi: 10.1186/s12859-023-05143-0.
5
Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward.预防性HIV疫苗——借鉴过往经验，铺就前行道路。
Vaccines (Basel). 2021 Sep 8;9(9):1001. doi: 10.3390/vaccines9091001.
6
Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.利用干扰素刺激基因 15 作为免疫佐剂增强 HIV-1Env 特异性 CD8 T 细胞应答。
J Virol. 2020 Dec 22;95(2). doi: 10.1128/JVI.01155-20.
7
Flagellin/NLRC4 Pathway Rescues NLRP3-Inflammasome Defect in Dendritic Cells From HIV-Infected Patients: Perspective for New Adjuvant in Immunocompromised Individuals.鞭毛蛋白/NLRC4 通路挽救 HIV 感染患者树突状细胞中 NLRP3 炎症小体缺陷：免疫功能低下个体新型佐剂的新视角。
Front Immunol. 2019 Jun 11;10:1291. doi: 10.3389/fimmu.2019.01291. eCollection 2019.
8
HIV vaccine research in Canada.加拿大的艾滋病疫苗研究。
AIDS Res Ther. 2017 Sep 12;14(1):54. doi: 10.1186/s12981-017-0181-8.
本文引用的文献
1
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.用包裹在纳米颗粒中的Toll样受体配体辅助猿猴免疫缺陷病毒疫苗可诱导持续性抗体反应并增强对TRIM5α限制型猕猴的保护。
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.
2
HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy.在抗逆转录病毒治疗期间，HIV持续存在于来自结肠和血液的CCR6+CD4+ T细胞中。
AIDS. 2017 Jan 2;31(1):35-48. doi: 10.1097/QAD.0000000000001309.
3
Understanding the regulation of pattern recognition receptors in inflammatory diseases - a 'Nod' in the right direction.了解炎症性疾病中模式识别受体的调控——朝着正确方向“点头”。
Immunology. 2017 Mar;150(3):237-247. doi: 10.1111/imm.12677. Epub 2016 Nov 14.
4
Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.用于共递送 HIV-1 CD8+ T 细胞表位和 Toll 样受体 7/8 激动剂 R848 的自组装肽，以诱导单核细胞来源的树突状细胞成熟并增强多功能细胞毒性 T 淋巴细胞 (CTL)反应。
J Control Release. 2016 Aug 28;236:22-30. doi: 10.1016/j.jconrel.2016.06.019. Epub 2016 Jun 11.
5
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.针对HIV的广泛中和抗体及其在疫苗设计中的作用。
Annu Rev Immunol. 2016 May 20;34:635-59. doi: 10.1146/annurev-immunol-041015-055515.
6
Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands.通过纳米颗粒载体包封 NOD 配体将疫苗免疫反应引导至黏膜。
Biomaterials. 2016 Jan;75:327-339. doi: 10.1016/j.biomaterials.2015.10.034. Epub 2015 Nov 3.
7
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.对Phambili 2b期HIV-1疫苗随机试验参与者的持续随访表明，接种疫苗的男性感染HIV-1的几率增加。
PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.
8
CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection.CD40L佐剂DNA/改良安卡拉痘苗病毒猿猴免疫缺陷病毒（SIV）疫苗增强了对中和抗性黏膜SIV感染的保护作用。
J Virol. 2015 Apr;89(8):4690-5. doi: 10.1128/JVI.03527-14. Epub 2015 Feb 4.
9
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.DNA疫苗分子佐剂SP-D-BAFF和SP-D-APRIL增强抗gp120免疫反应并提高HIV-1中和抗体滴度。
J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.
10
Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.抗体持久性与T细胞平衡：HIV疫苗研发面临的两个关键因素。
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21. doi: 10.1073/pnas.1413550111. Epub 2014 Oct 27.
Zotero 插件